About two thirds of House Republicans voted to back Trump’s effort to overturn his November election loss just hours after his supporters’ deadly siege of the Capitol. “People have been lied to,” she said Sunday. “The extent to which the president, President Trump, for months leading up to Jan.

“I don’t think COVID’s going to be able to stop us from jumping up and down, and fist bumping,” he said. “You’re going to see a lot of happy people no matter what, once we get this thing on the surface safely.” ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

The vaccine has already been rolled out to key groups at higher risk of exposure to coronavirus but Saturday approval allows for its use on the general public.A conditional approval helps hustle emergency drugs to market in cases when clinical trials are yet to meet normal standards but indicate therapies will work.The approval comes after multiple domestic and overseas trials of the vaccine in countries including Brazil and Turkey, although “efficacy and safety results need to be further confirmed”, Sinovac said in a statement.Fellow Chinese pharmaceutical company Sinopharm received a similar conditional green light in December to put its vaccine on the market.Sinovac said trials in Brazil had shown around 50 percent efficacy in preventing infection and 80 percent efficacy in preventing cases requiring medical intervention.”The results show that the vaccine has good safety and immunogenic effect on people of all age groups,” Sinovac said Saturday.Meanwhile Sinopharm said in December that its vaccine had a 79.34 percent efficacy rate, lower than rival jabs developed in the West by Pfizer BioNTech and Moderna with 95 and 94 percent rates respectively.China has been racing to develop homegrown jabs and aims to vaccinate 50 million people before the start of the Lunar New Year in mid February.Beijing has also pledged to share the vaccine at a fair cost a potential boost for poorer Asian countries who are otherwise reliant on limited distribution offered by the Covax scheme.Countries including Senegal, Indonesia, and Hungary have procured millions of vaccine doses from Chinese pharmaceutical firms.But take up has been slower abroad for Chinese vaccines compared to jabs from Pfizer BioNTech and Moderna, as little information has been published about the safety or efficacy of Chinese vaccines.Chinese vaccine makers also have chequered reputations, after major scandals at home involving expired or poor quality products.Internet access restored as Myanmar coup protests growAs enthusiastic crowds of tens of thousands marched through the streets of Myanmar’s biggest city on Sunday to protest last week’s coup ousting Aung San Suu Kyi elected government, their spirits were lifted by the return of internet services that had been blocked a day earlier. Separate protests that began in various parts of Yangon converged at Sule Pagoda, situated in the center of a roundabout in the city’s downtown area. Protesters chanted “Long live Mother Suu” and “Down with military dictatorship.”UK vaccine gambles paid off, while EU caution slowed it downSAINT HERBLAIN, France (AP) French pharmaceutical startup Valneva had big news in September: a government contract for 60 million doses of its coronavirus vaccine candidate.